AGI Significance Paradox: As progress accelerates towards AGI, the number of people who realize the significance of each new breakthrough decreases.
More from Carlos E. Perez
More from Science
If this is true raises the question of why certain (fringe & unethical) views got access to No.10 while others were ignored... https://t.co/A75HrSEqo4
— Prof. Devi Sridhar (@devisridhar) December 13, 2020
I want to talk about 3 things:
‼️Their fringe views are inhumane, unethical junk science that promotes harm
‼️They complain that they've been marginalized but this is simply untrue
‼️I am sick of people telling me we have to "listen to both sides." There aren't 2 sides here 2/n
These 'dissident' scientists have consistently downplayed COVID-19, urging policymakers not to take aggressive control measures. They claim it is not a serious threat. Gupta even went on TV saying people under 65 shouldn't worry about it!
RECEIPTS
They have consistently argued that policymakers should just let the virus rip, in an attempt to reach herd immunity by natural infection. Kuldorff *continues* to argue for this even now that we have many highly effective, safe vaccines.
Focused Protection: The Middle Ground between Lockdowns and "Let-it-rip". An essay by Jay Bhattacharya (@Stanford), @SunetraGupta (@UniofOxford) and @MartinKulldorff (@Harvard). https://t.co/T8uLxSFwgh
— Martin Kulldorff (@MartinKulldorff) December 11, 2020
We've never controlled a deadly, contagious pandemic before by just letting the virus spread, as this approach kills & disables too many people. In Manaus, Brazil, 66% of the city was infected & an astonishing *1 in 500* people died of COVID-19
A thread on the potential near term catalysts behind why I have increased my position in 4d Pharma @4dpharmaplc (LON: #DDDD):

1) NASDAQ listing. This is the most obvious.
The idea behind this is that the huge pool of capital and institutional interest in the NASDAQ will enable a higher per-share valuation for #DDDD than was achievable in the UK.
Comparators to @4dpharmaplc #DDDD (market capitalisation £150m) on the NASDAQ and their market capitalisation:
Seres Therapeutics: $2.33bn = £1.72bn (has had a successful phase 3 C. difficile trial); from my previous research (below) the chance of #DDDD achieving this at least once is at least
While looking at speculative pharmaceutical stocks I am reminded of why I am averse to these risky picks.#DDDD was compelling enough, though, to break this rule. The 10+ treatments under trial, industry-leading IP portfolio, and comparable undervaluation are inescapable.
— Shrey Srivastava (@BlogShrey) December 16, 2020
Kaleido Biosciences: $347m = £256m. 4 products under consideration, compared to #DDDD's potential 16. When you view @4dpharmaplc's 1000+ patents and AI-driven MicroRx platform (not to mention their end-to-end manufacturing capability), 4d's undervaluation is clear.
Thank you again @JamesEBartlett for a fantastic talk (with a really nice personal touch) on reproducible workflows!
— RIOT Science Club Wolverhampton (@riotscience_wlv) February 16, 2021
Thanks especially for the co-leads @IMLahart for co-hosting and @DrManiBhogal for nabbing James!
Slides: https://t.co/CNqxzOhch1
Video: https://t.co/YjHEHuRJlz
My inspiration was making open science accessible. I wanted to outline the mistakes I've made along the way so people would feel empowered to give it a go. Increased accountability is seen as a barrier to adopting open science practices as an ECR
It also comes across as all or nothing. You are either fully open science or your research won't get anywhere. However, that can be quite intimidating, so I wanted to emphasise this incremental approach to adapting your workflow
There are two sides to why you should work towards reproducibility. The first is communal. It's going to help the field if you or someone else can reproduce your whole pipeline.

There is also the selfish element of it's just going to help you do your work. If you can't remember what your work means after a lunch break, you're not going to remember months or years down the line
Why are lunch breaks important for #code?
— Dr Rebecca Hirst (@HirstRj) February 11, 2021
If you can't remember what your variable names refer to after lunch, you sure as hell won't remember in 3 months.